-$0.67 EPS Expected for Proteostasis Therapeutics Inc (PTI) This Quarter

Equities research analysts expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to report earnings of ($0.67) per share for the current quarter, Zacks reports. Two analysts have made estimates for Proteostasis Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at ($0.61). Proteostasis Therapeutics posted earnings per share of ($0.38) during the same quarter last year, which suggests a negative year-over-year growth rate of 76.3%. The company is scheduled to announce its next earnings results on Thursday, March 29th.

On average, analysts expect that Proteostasis Therapeutics will report full year earnings of ($2.50) per share for the current year, with EPS estimates ranging from ($2.56) to ($2.44). For the next year, analysts forecast that the firm will post earnings of ($2.36) per share, with EPS estimates ranging from ($2.82) to ($1.89). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.16. The business had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%.

Several analysts recently issued reports on PTI shares. Robert W. Baird upped their price target on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. ValuEngine cut shares of Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Leerink Swann upped their price target on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a report on Tuesday, December 19th. Finally, Zacks Investment Research cut shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Proteostasis Therapeutics currently has a consensus rating of “Hold” and an average price target of $16.00.

In other Proteostasis Therapeutics news, major shareholder Enterprise Associates 12 New bought 2,000,000 shares of the company’s stock in a transaction on Monday, December 18th. The shares were bought at an average cost of $5.00 per share, with a total value of $10,000,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Cormorant Asset Management, Ll sold 504,027 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $4.88, for a total transaction of $2,459,651.76. The disclosure for this sale can be found here. Insiders have acquired 2,100,000 shares of company stock worth $10,500,000 over the last three months. 17.40% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the business. Susquehanna International Group LLP acquired a new stake in shares of Proteostasis Therapeutics in the 2nd quarter worth about $254,000. FMR LLC increased its holdings in shares of Proteostasis Therapeutics by 2.3% in the 2nd quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after acquiring an additional 66,111 shares during the period. Jennison Associates LLC increased its holdings in shares of Proteostasis Therapeutics by 53.5% in the 4th quarter. Jennison Associates LLC now owns 3,178,432 shares of the company’s stock worth $18,530,000 after acquiring an additional 1,107,496 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Proteostasis Therapeutics in the 2nd quarter worth about $296,000. Finally, Sabby Management LLC increased its holdings in shares of Proteostasis Therapeutics by 109.6% in the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after acquiring an additional 65,451 shares during the period. 55.15% of the stock is currently owned by institutional investors.

Proteostasis Therapeutics (NASDAQ PTI) traded down $0.21 on Monday, reaching $2.90. 467,172 shares of the company traded hands, compared to its average volume of 820,666. The firm has a market capitalization of $102.98, a PE ratio of -1.31 and a beta of 6.35. Proteostasis Therapeutics has a 1 year low of $1.41 and a 1 year high of $16.67.

COPYRIGHT VIOLATION WARNING: “-$0.67 EPS Expected for Proteostasis Therapeutics Inc (PTI) This Quarter” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://stocknewstimes.com/2018/02/17/0-67-eps-expected-for-proteostasis-therapeutics-inc-pti-this-quarter.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply